This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CERC Cerecor (CERC) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Cerecor Stock (NASDAQ:CERC) Get Cerecor alerts:Sign Up Key Stats Today's Range$14.11▼$16.6650-Day Range$2.06▼$3.2452-Week Range$1.98▼$4.50Volume1.58 million shsAverage Volume1.27 million shsMarket Capitalization$1.38 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Cerecor, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD. Read More Receive CERC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cerecor and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CERC Stock News HeadlinesAytu BioPharma Stock (NASDAQ:AYTU) Insider TradesDecember 19, 2023 | benzinga.commTOR Inhibitors Global Market Report 2023August 24, 2023 | uk.finance.yahoo.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.September 15 at 1:00 AM | Base Camp Trading (Ad)DelveInsight Highlights Major Advances, Transformative Therapies, and 80+ Leading Players Wheeling the Crohn's Disease Pipeline LandscapeMay 11, 2023 | finance.yahoo.comEdited Transcript of AYTU.OQ earnings conference call or presentation 27-Sep-22 8:30pm GMT - Yahoo FinanceSeptember 28, 2022 | finance.yahoo.comAytu BioPharma, Inc. (AYTU) CEO Josh Disbrow on Q4 2022 Results - Earnings Call Transcript - Seeking AlphaSeptember 28, 2022 | seekingalpha.comDiGeorge Syndrome Drug Market In-Depth Analysis Research Report 2029August 31, 2022 | marketwatch.comValenzaBio Appoints Industry Veteran Peter Greenleaf to its Board of Directors - StreetInsider.comAugust 24, 2022 | streetinsider.comSee More Headlines CERC Stock Analysis - Frequently Asked Questions How were Cerecor's earnings last quarter? Cerecor Inc. (NASDAQ:CERC) posted its quarterly earnings data on Sunday, August, 1st. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.17) by $0.01. The firm had revenue of $3.36 million for the quarter. Cerecor had a negative trailing twelve-month return on equity of 261.82% and a negative net margin of 1,194.82%. What other stocks do shareholders of Cerecor own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cerecor investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), OPKO Health (OPK), VBI Vaccines (VBIV), Pfizer (PFE) and Agile Therapeutics (AGRX). Company Calendar Last Earnings8/01/2021Today9/15/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CERC CIK1534120 Webwww.cerecor.com Phone(410) 522-8707FaxN/AEmployees31Year Founded2011Profitability EPS (Trailing Twelve Months)($0.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$63.50 million Net Margins-1,194.82% Pretax MarginN/A Return on Equity-261.82% Return on Assets-133.96% Debt Debt-to-Equity Ratio0.79 Current Ratio2.19 Quick Ratio2.18 Sales & Book Value Annual Sales$6.70 million Price / Sales206.49 Cash FlowN/A Price / Cash FlowN/A Book Value$0.22 per share Price / Book65.50Miscellaneous Outstanding Shares96,009,000Free FloatN/AMarket Cap$1.38 billion OptionableNot Optionable Beta1.44 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:CERC) was last updated on 9/15/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cerecor Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cerecor With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
